But abstinence is often a significant bar comparable to necessitating that an antidepressant make total remission of depression or that an analgesic completely remove pain. Recognizing this limitation, the FDA encourages builders of opioid2 and stimulant3 use condition remedies to discuss with FDA substitute strategies to evaluate changes in drug u